DWA
SNDX icon

Dorsey Wright & Associates’s Syndax Pharmaceuticals SNDX Stock Holding History

Dorsey Wright & Associates’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,410
Closed -$31.5K – 350
2021
Q1 		$31.5K Buy
1,410
+810
+135% +$18.3K 0.37% 145
2020
Q4 		$13K Buy
+600
New +$12.4K ﹤0.01% 270
2020
Q2 		– Sell
-803
Closed -$9K – 358
2020
Q1 		$9K Buy
+803
New +$7.54K ﹤0.01% 169
2019
Q4 		– Sell
-1,065
Closed -$8K – 339
2019
Q3 		$8K Buy
+1,065
New +$9.7K ﹤0.01% 282

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dorsey Wright & Associates's SNDX Position: Q2 2021 in Review

Dorsey Wright & Associates sold out of Syndax Pharmaceuticals (SNDX) in Q2 2021, closing a stake of 1,410 shares — an estimated $31.5K sold.

Dorsey Wright & Associates first reported a position in SNDX in Q3 2019 and held it in 4 quarters. The position peaked at $31.5K in Q1 2021. 115 funds tracked by Wall St. Rank hold SNDX as of Q2 2021.

  • Dorsey Wright & Associates reported no remaining Syndax Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,410 Syndax Pharmaceuticals shares in Q2 2021, an estimated $31.5K.
  • Dorsey Wright & Associates first reported a position in Syndax Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Dorsey Wright & Associates's Syndax Pharmaceuticals position peaked at $31.5K in Q1 2021.
  • 115 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2021.

Based on Dorsey Wright & Associates's 13F filing for Q2 2021, filed 23 Jul 2021.